Luminex Corp (LMNX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Luminex Corp (LMNX:NASDAQ), powered by AI.

Current Price
$17.37
Sector
Healthcare
What is the Luminex Corp stock price forecast?

Luminex Corp is currently trading at $17.37. View real-time AI analysis on Alpha Lenz.

What is Luminex Corp insider trading activity?

View the latest insider trading data for Luminex Corp on Alpha Lenz.

What is Luminex Corp's P/E ratio?

View Luminex Corp's valuation metrics on Alpha Lenz.

Luminex Corp

$17.37
NASDAQLMNX
Ask about Luminex Corp's future dividend policy...

Company Overview

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

CEOMr. Nachum Shamir
SectorHealthcare
IndustryMedical Instruments & Supplies
Employees1,325

Company Statistics

Profile

Market CapN/A
RevenueN/A
Shares Out0.00
Employees1,325

Margins

GrossN/A
EBITDAN/A
OperatingN/A
Pre-TaxN/A
NetN/A

Valuation

P/EN/A
P/BN/A
EV/SalesN/A
EV/EBITDAN/A
P/FCFN/A

Growth (CAGR)

Rev 3YrN/A
Rev 5YrN/A
Op Inc 3YrN/A
Op Inc 5YrN/A
Net Inc 3YrN/A
Net Inc 5YrN/A

Returns

ROAN/A
ROEN/A
ROICN/A

Financial Health

Cash & Cash EquivalentsN/A
Net DebtN/A
Debt/EquityN/A
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Luminex Corp (Healthcare) Stock Forecast & Analysis $17.37 | Alpha Lenz